

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/661,693-Conf. #2096	
Sheet	1	of	2	Filing Date	September 14, 2000
				First Named Inventor	S. Indiran Pather
				Art Unit	1616
				Examiner Name	M. Lamm
				Attorney Docket Number	CIMA 3.0-030 CONT CONT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
lll	AA	US-2004/0213855	10-28-2004	PETTERSON ET AL.	
	AB	US-3,962,417	06/1976	HOWELL	
	AC	US-4,613,497	09/1986	CHAUKIN	
	AD	US-4,687,662	08/1987	SCHOBEL	
	AE	US-4,725,427	02/1988	ASHMEAD	
	AF	US-4,753,792	06/1988	ABERG	
	AG	US-4,863,737	09-05-1989	STANLEY ET AL.	
	AH	US-4,940,588	07/1990	SPARKS	
	AI	US-5,055,306	02/1991	BARRY	
	AJ	US-5,464,632	11/1995	COUSINS	
	AK	US-5,550,861	03-26-1998	MAKINO	
	AL	US-5,720,974	02-24-1998	MAKINO	
	AM	US-5,785,989	07-28-1998	STANLEY ET AL.	
	AN	US-5,958,468	09/1999	NORLING ET AL.	
	AO	US-6,106,861	08-22-2000	CHEVEAU	
	AP	US-6,155,423	12-05-2000	KATZNER et al.	
	AQ	US-6,368,625	04-09-2002	SIEBERT et al.	
	AR	US-6,680,071	01-20-2004	JOHNSON ET AL.	
	AS	US-6,759,059	07-06-2004	PETTERSON ET AL.	
	AT	US-6,761,910	07-13-2004	PETTERSON ET AL.	
lll	AU*	US-Application No. 10/936,185		PATHER ET AL.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)				
lll	BA	WO-96/29993-A1	10-03-1996	Hesnard, Xavier		✓
lll	BB	GB-3160	10-24-1872	COOPER		
lll	BC	WO-2004/067004	08-12-2004	OREXO AB		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
lll	CA	HELENE HAGERSTROM, "Polymer Gels as Pharmaceutical Dosage Forms" Thesis (Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 293) 2003	
lll	CB	SUSANNE BREDENBERG, "New Concepts in Administration of Drugs in Tablet Form" Thesis (comprehensive summaries of Uppsala Dissertations from the Faculty of Pharmacy 287) 2003	
Examiner Signature			Date Considered
		10/12/05	



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/661,693-Conf. #2096
				Filing Date	September 14, 2000
				First Named Inventor	S. Indiran Pather
				Art Unit	1616
				Examiner Name	M. Lamm
				Attorney Docket Number	CIMA 3.0-030 CONT CONT
Sheet	2	of	2		


CC	Pharmaceutical Dosage Forms - Tablets vol. 1, 2nd ed., Herbert A. Lieberman, ed. pp. 972-76.	
CD	PATHER et al., "Buccal Delivery - Enhanced Buccal Delivery of Fentanyl Using the Oravescent Drug Delivery System", Drug Delivery Tech., Vol. 1, No. 1, October 2001.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/12/05
-----------------------	--	--------------------	----------

577159



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/661,693-Conf. #2096	
			Filing Date	September 14, 2000	
			First Named Inventor	S. Indiran Pather	
			Art Unit	1616	
			Examiner Name	M. Lamm	
Sheet	1	of	2	Attorney Docket Number	CIMA 3.0-030 CONT CONT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (# known)			
u	AA	US-1,262,888	04/1918	Preble, W.P. et al.	
	AB	US-3,577,490	05/1971	Welsh, T. L. et al.	
	AC	US-3,888,976	06/1975	Mlkvy et al.	
	AD	US-3,961,041	06/1976	Nishimura et al.	
	AE	US-4,147,768	04/1979	Schaffer et al.	
	AF	US-4,187,286	02/1980	MARCUS, B.J.	
	AG	US-4,289,751	09/1981	Windheuser	
	AH	US-4,503,031	03/1985	Glassman	
	AI	US-4,599,342	07/1986	LAHANN, THOMAS R.	
	AJ	US-4,671,953	06/1987	STANLEY ET AL.	
	AK	US-4,756,710	07-12-1988	Bondi et al.	
	AL	US-5,073,374	12/1991	MCCARTY, JOHN A.	
	AM	US-5,468,504	11/1995	Schaeffer, Alain E. E.	
	AN	US-5,503,846	04-02-1996	Wehling et al.	
	AO	US-5,559,096	09/1996	Edwards et al.	
	AP	US-5,624,687	04-29-1997	Yano et al.	
	AQ	US-5,626,866	05-06-1997	Ebert et al.	
	AR	US-5,646,151	07/1997	Kruse et al.	
	AS	US-5,853,748	12-29-1998	New	
	AT	US-5,900,252	05-04-1999	Calanchi et al.	
	AU	US-5,952,004	09-14-1999	Rudnic et al.	
	AV	US-6,034,085	03-07-2000	Joshi et al.	
	AW	US-6,068,853	05-30-2000	Giannos et al.	
	AX	US-6,129,906	10/2000	Steventon	
	AY	US-6,200,604	03-13-2001	Pather et al.	
	AZ	US-6,316,027-B1	11-13-2001	Clarke, Anthony et al.	
	AA1	US-6,350,470-B1	02/2002	Pather et al.	
	AB1	US-6,391,335	05-21-2002	Pather et al.	
	AC1	US-6,488,961	12/2002	ROBINSON ET AL.	
	AD1	US-6,509,036	01-21-2003	Pather et al.	
u	AE1	US-6,576,250-B1	06/2003	Pather et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)				
u	BA	EP-0 197 504-A1	10-15-1986	Bondi et al.		
	BB	EP-0 354 973-B2	02-21-1990	Paradissis		
	BC	EP-0361680-A2	04/1990	MICHELL		
	BD	GB-2307857-A	06/1997	LESLIE ET AL.		
	BE	WO-95/27482-A1	10/1995	FREEMAN ET AL.		
	BF	WO-95/34291-A1	12-21-1995	JENSEN LINE NOERGAARD		
	BG	WO-97/17067-A1	05-15-1997	Somerset Pharmaceuticals Inc.		
u						

Examiner Signature		Date Considered	10/16/00
-----------------------	--	--------------------	----------

576248



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/661,693-Conf. #2096
				Filing Date	September 14, 2000
				First Named Inventor	S. Indiran Pather
				Art Unit	1616
				Examiner Name	M. Lamm
Sheet	2	of	2	Attorney Docket Number	CIMA 3.0-030 CONT CONT

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
uu	CA	AMIGHI, K.; TIMMERMANS, J.; PUIGDEVALL, J.; BALTES, E.; MOËS, A. J.; Peroral Sustained-Release Film-Coated Pellets as a Means to Overcome Physicochemical and Biological Drug-Related Problems. I. In Vitro Development and Evaluation, Drug Development and Industrial Pharmacy, 1998, pp. 509-515, vol. 24, no. 6.	
	CB	BERKO, S.; REGDON JUN, G.; ERÖS, I.; Influence of pH Change on Drug Release from Rectal Suppositories, Die Pharmazie, April 2000, p.324, Vol. 55., Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn.	
	CC	GIANNOS, S.A.; DINH, S.M.; BERNER, B.; Temporally Controlled Drug Delivery Systems: Coupling of pH Oscillators with Membrane Diffusion, Journal of Pharmaceutical Sciences, May 1995, pp. 539-543, Vol. 84, No. 5.	
	CD	Nishimura et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa VI: Formulation of Effervescent Enteric-Coated Tablets" J. Pharm. Sci. 73(7):942-46 (1984).	
	CE	RANADE, V.V.; Drug Delivery Systems Part 5B. Oral Drug Delivery, The Journal of Clinical Pharmacology, Feb. 1991, pp. 98-115, Vol. 31.	
	CF	Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa II: Bioavailability of Marketed Levodopa Preparations in Dogs and Parkinsonian Patients" J. Pharm. Sci. 69(3):261-65 (1980).	
	CG	Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa III: Influence of Dose on Pharmacokinetic Behavior of Levodopa in Dogs and Parkinsonian Patients" J. Pharm. Sci. 69(12):1374-78 (1980).	
	CH	Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa V: Absorption and Metabolism of Levodopa in Intestinal Segments of Dogs" J. Pharm. Sci. 70(10):1157-60 (1981).	
	CI	Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa IV: Possible Causes of Low Bioavailability of Oral Levodopa in Dogs" J. Pharm. Sci. 70(7):730-33 (1981).	
	CJ	SORASUCHART, W.; WARDROP, J.; AYERS, J.; Drug Release from Spray Layered and Coated Drug-Containing Beads: Effects of pH and Comparison of Different Dissolution Methods, Drug Development and Industrial Pharmacy, 1999, pp. 1093-1098, Vol. 25, No. 10	
uu	CK	STREUBEL, A.; SIEPMANN, J.; DASHEVSKY, A.; BODMEIER, R.; pH-Independent Release of a Weakly Basic Drug from Water-Insoluble and -Soluble Matrix Tablets, Journal of Controlled Release, 2000, pp. 101-110, Vol. 67.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/12/05
--------------------	--	-----------------	----------

578248